Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.99
+3.5%
$4.82
$1.58
$6.44
$533.13M0.891.38 million shs5.07 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.13
-1.7%
$1.21
$0.66
$5.92
$129.50M2.182.18 million shs972,860 shs
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$6.61
-1.3%
$6.33
$4.95
$12.83
$472.23M0.94713,905 shs274,054 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$18.48
-0.6%
$17.15
$11.56
$29.79
$474.66M2254,906 shs120,341 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+3.45%+13.02%+15.86%+93.23%+254.44%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-1.74%-1.74%-6.61%+1.80%-74.66%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
-1.34%-2.36%+2.96%+10.35%-26.64%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-0.65%+2.78%+9.80%+15.43%+21.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.4914 of 5 stars
3.61.00.00.03.51.70.6
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3.6581 of 5 stars
3.11.00.04.71.91.70.6
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.0205 of 5 stars
0.03.00.00.01.50.83.1
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
1.9924 of 5 stars
3.51.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.14
Buy$20.20237.23% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.13
Hold$3.83239.23% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33166.96% Upside

Current Analyst Ratings Breakdown

Latest FATE, ATYR, SIGA, and TRML Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/4/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/19/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/23/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,317.87N/AN/A$0.83 per share7.22
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M9.50N/AN/A$2.80 per share0.40
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$138.72M3.40$0.84 per share7.90$3.02 per share2.19
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.81N/AN/AN/AN/A-87.09%-64.77%8/12/2025 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$0.679.875.29N/A40.30%25.21%22.05%7/30/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest FATE, ATYR, SIGA, and TRML Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.95N/AN/AN/AN/AN/A
8/12/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.34N/AN/AN/A$1.16 millionN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
5/8/2025Q1 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
5/7/2025Q1 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.19-$0.17+$0.02-$0.17N/AN/A
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
7.79
7.79
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.81
8.81
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
8.40
6.28
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.51%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.95%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5389.00 million85.71 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.29 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.44 million70.05 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.68 million22.35 millionOptionable

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
Tourmaline Bio initiated with a Buy at Chardan
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.99 +0.20 (+3.45%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.16 +0.18 (+2.92%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.13 -0.02 (-1.74%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.18 +0.05 (+4.34%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$6.61 -0.09 (-1.34%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.61 0.00 (0.00%)
As of 07/18/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$18.48 -0.12 (-0.65%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$18.92 +0.45 (+2.41%)
As of 07/18/2025 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.